Imetelstat: a new addition to the therapeutic landscape of lower-risk MDS

2.

Greenberg

P

,

Cox

C

,

LeBeau

MM

, et al.

International scoring system for evaluating prognosis in myelodysplastic syndromes

.

Blood

.

1997

;

89

(

6

):

2079

-

2088

.

3.

Carraway

HE

,

Saygin

C

.

Therapy for lower-risk MDS

.

Hematology Am Soc Hematol Educ Program

.

2020

;

2020

(

1

):

426

-

433

.

4.

Platzbecker

U

,

Hofbauer

LC

,

Ehninger

G

,

Hölig

K

.

The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

.

Leuk Res

.

2012

;

36

(

5

):

525

-

536

.

5.

Stauder

R

,

Yu

G

,

Koinig

KA

, et al.

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

.

Leukemia

.

2018

;

32

(

6

):

1380

-

1392

.

6.

Anand

I

,

McMurray

JJ

,

Whitmore

J

, et al.

Anemia and its relationship to clinical outcome in heart failure

.

Circulation

.

2004

;

110

(

2

):

149

-

154

.

7.

de Swart

L

,

Crouch

S

,

Hoeks

M

, et al.

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes

.

Haematologica

.

2020

;

105

(

3

):

632

-

639

.

8.

Harnan

S

,

Ren

S

,

Gomersall

T

, et al.

Association between transfusion status and overall survival in patients with myelodysplastic syndromes: a systematic literature review and meta-analysis

.

Acta Haematol

.

2016

;

136

(

1

):

23

-

42

.

9.

Fenaux

P

,

Ades

L

.

How we treat lower-risk myelodysplastic syndromes

.

Blood

.

2013

;

121

(

21

):

4280

-

4286

.

10.

Greenberg

PL

,

Tuechler

H

,

Schanz

J

, et al.

Revised international prognostic scoring system for myelodysplastic syndromes

.

Blood

.

2012

;

120

(

12

):

2454

-

2465

.

11.

Bernard

E

,

Tuechler

H

,

Greenberg

PL

, et al.

Molecular international prognostic scoring system for myelodysplastic syndromes

.

NEJM Evid

.

2022

;

1

(

7

):

EVIDoa2200008

.

12.

Park

S

,

Hamel

JF

,

Toma

A

, et al.

Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents

.

J Clin Oncol

.

2017

;

35

(

14

):

1591

-

1597

.

13.

Tentori

CA

,

Gregorio

C

,

Robin

M

, et al.

Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes

.

J Clin Oncol

.

2024

;

42

(

24

):

2873

-

2886

.

14.

Platzbecker

U

,

Santini

V

,

Fenaux

P

, et al.

Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet

.

2024

;

403

(

10423

):

249

-

260

.

15.

Della Porta

MG

,

Garcia-Manero

G

,

Santini

V

, et al.

Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial

.

Lancet Haematol

.

2024

;

11

(

9

):

e646

-

e658

.

16.

Greenberg

PL

,

Stone

RM

,

Al-Kali

A

, et al.

NCCN guidelines(R) insights: myelodysplastic syndromes, version 3.2022

.

J Natl Compr Canc Netw

.

2022

;

20

(

2

):

106

-

117

.

17.

Fenaux

P

,

Santini

V

,

Spiriti

MAA

, et al.

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS

.

Leukemia

.

2018

;

32

(

12

):

2648

-

2658

.

18.

Platzbecker

U

,

Symeonidis

A

,

Oliva

EN

, et al.

A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes

.

Leukemia

.

2017

;

31

(

9

):

1944

-

1950

.

19.

Greenberg

PL

,

Sun

Z

,

Miller

KB

, et al.

Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)

.

Blood

.

2009

;

114

(

12

):

2393

-

2400

.

20.

Santini

V

,

Schemenau

J

,

Levis

A

, et al.

Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?

.

Blood

.

2013

;

122

(

13

):

2286

-

2288

.

21.

Hellstrom-Lindberg

E

,

Gulbrandsen

N

,

Lindberg

G

, et al.

A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life

.

Br J Haematol

.

2003

;

120

(

6

):

1037

-

1046

.

22.

Park

S

,

Grabar

S

,

Kelaidi

C

, et al.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience

.

Blood

.

2008

;

111

(

2

):

574

-

582

.

23.

Jadersten

M

,

Malcovati

L

,

Dybedal

I

, et al.

Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome

.

J Clin Oncol

.

2008

;

26

(

21

):

3607

-

3613

.

24.

Toma

A

,

Kosmider

O

,

Chevret

S

, et al.

Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion

.

Leukemia

.

2016

;

30

(

4

):

897

-

905

.

25.

Raza

A

,

Reeves

JA

,

Feldman

EJ

, et al.

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q

.

Blood

.

2008

;

111

(

1

):

86

-

93

.

26.

Thepot

S

,

Ben Abdelali

R

,

Chevret

S

, et al.

A randomized phase II trial of azacitidine +/- epoetin-beta in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents

.

Haematologica

.

2016

;

101

(

8

):

918

-

925

.

27.

Santini

V

,

Almeida

A

,

Giagounidis

A

, et al.

Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents

.

J Clin Oncol

.

2016

;

34

(

25

):

2988

-

2996

.

28.

Komrokji

R

,

Swern

AS

,

Grinblatt

D

, et al.

Azacitidine in lower-risk myelodysplastic syndromes: a meta-analysis of data from prospective studies

.

Oncologist

.

2018

;

23

(

2

):

159

-

170

.

29.

List

AF

,

Sun

Z

,

Verma

A

, et al.

Lenalidomide-epoetin alfa versus lenalidomide monotherapy in myelodysplastic syndromes refractory to recombinant erythropoietin

.

J Clin Oncol

.

2021

;

39

(

9

):

1001

-

1009

.

30.

Zhou

L

,

Nguyen

AN

,

Sohal

D

, et al.

Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS

.

Blood

.

2008

;

112

(

8

):

3434

-

3443

.

31.

Suragani

RN

,

Cadena

SM

,

Cawley

SM

, et al.

Transforming growth factor-beta superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis

.

Nat Med

.

2014

;

20

(

4

):

408

-

414

.

32.

Kubasch

AS

,

Fenaux

P

,

Platzbecker

U

.

Development of luspatercept to treat ineffective erythropoiesis

.

Blood Adv

.

2021

;

5

(

5

):

1565

-

1575

.

33.

Platzbecker

U

,

Germing

U

,

Gotze

KS

, et al.

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

.

Lancet Oncol

.

2017

;

18

(

10

):

1338

-

1347

.

34.

Fenaux

P

,

Platzbecker

U

,

Mufti

GJ

, et al.

Luspatercept in patients with lower-risk myelodysplastic syndromes

.

N Engl J Med

.

2020

;

382

(

2

):

140

-

151

.

35.

Zeidan

AM

,

Platzbecker

U

,

Garcia-Manero

G

, et al.

Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts

.

Blood

.

2022

;

140

(

20

):

2170

-

2174

.

36.

Platzbecker

U

,

Della Porta

MG

,

Santini

V

, et al.

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial

.

Lancet

.

2023

;

402

(

10399

):

373

-

385

.

37.

Herbert

BS

,

Gellert

GC

,

Hochreiter

A

, et al.

Lipid modification of GRN163, an N3'→P5' thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition

.

Oncogene

.

2005

;

24

(

33

):

5262

-

5268

.

38.

Asai

A

,

Oshima

Y

,

Yamamoto

Y

, et al.

A novel telomerase template antagonist (GRN163) as a potential anticancer agent

.

Cancer Res

.

2003

;

63

(

14

):

3931

-

3939

.

39.

Park

HS

,

Choi

J

,

See

CJ

, et al.

Dysregulation of telomere lengths and telomerase activity in myelodysplastic syndrome

.

Ann Lab Med

.

2017

;

37

(

3

):

195

-

203

.